Incyte Corporation (0J9P.L)
USD 57.71
(-1.8%)
USD 57.71
(-1.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.78 Billion USD | 16.11% |
| 2022 | 5.84 Billion USD | 18.4% |
| 2021 | 4.93 Billion USD | 38.54% |
| 2020 | 3.56 Billion USD | 3.92% |
| 2019 | 3.42 Billion USD | 29.52% |
| 2018 | 2.64 Billion USD | 14.9% |
| 2017 | 2.3 Billion USD | 40.52% |
| 2016 | 1.63 Billion USD | 62.65% |
| 2015 | 1 Billion USD | 21.37% |
| 2014 | 830.06 Million USD | 31.85% |
| 2013 | 629.56 Million USD | 90.54% |
| 2012 | 330.41 Million USD | 0.44% |
| 2011 | 328.96 Million USD | -32.81% |
| 2010 | 489.58 Million USD | -31.28% |
| 2009 | 712.39 Million USD | 206.55% |
| 2008 | 232.38 Million USD | -15.71% |
| 2007 | 275.69 Million USD | -22.03% |
| 2006 | 353.6 Million USD | -5.48% |
| 2005 | 374.1 Million USD | -27.63% |
| 2004 | 516.91 Million USD | 36.19% |
| 2003 | 379.54 Million USD | -31.26% |
| 2002 | 552.13 Million USD | -21.74% |
| 2001 | 705.55 Million USD | -20.44% |
| 2000 | 886.82 Million USD | 299.65% |
| 1999 | 221.9 Million USD | -3.65% |
| 1998 | 230.3 Million USD | 19.26% |
| 1997 | 193.1 Million USD | 188.64% |
| 1996 | 66.9 Million USD | 15.74% |
| 1995 | 57.8 Million USD | 101.39% |
| 1994 | 28.7 Million USD | 63.07% |
| 1993 | 17.6 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.13 Billion USD | 5.21% |
| 2024 Q3 | 5.01 Billion USD | 7.52% |
| 2024 Q2 | 4.66 Billion USD | -34.67% |
| 2023 Q3 | 6.38 Billion USD | 2.9% |
| 2023 Q2 | 6.2 Billion USD | 7.08% |
| 2023 Q1 | 5.79 Billion USD | -0.74% |
| 2023 FY | 6.78 Billion USD | 16.11% |
| 2023 Q4 | 6.78 Billion USD | 6.17% |
| 2022 Q2 | 5.31 Billion USD | 5.24% |
| 2022 Q1 | 5.05 Billion USD | 2.45% |
| 2022 FY | 5.84 Billion USD | 18.4% |
| 2022 Q4 | 5.84 Billion USD | 6.0% |
| 2022 Q3 | 5.51 Billion USD | 3.59% |
| 2021 Q3 | 4.19 Billion USD | 7.53% |
| 2021 Q4 | 4.93 Billion USD | 17.49% |
| 2021 FY | 4.93 Billion USD | 38.54% |
| 2021 Q1 | 3.66 Billion USD | 2.82% |
| 2021 Q2 | 3.9 Billion USD | 6.64% |
| 2020 FY | 3.56 Billion USD | 3.92% |
| 2020 Q1 | 2.75 Billion USD | -19.68% |
| 2020 Q2 | 3.21 Billion USD | 16.71% |
| 2020 Q3 | 3.3 Billion USD | 2.96% |
| 2020 Q4 | 3.56 Billion USD | 7.66% |
| 2019 Q3 | 3.21 Billion USD | 9.06% |
| 2019 Q4 | 3.42 Billion USD | 6.59% |
| 2019 FY | 3.42 Billion USD | 29.52% |
| 2019 Q1 | 2.75 Billion USD | 4.1% |
| 2019 Q2 | 2.94 Billion USD | 7.02% |
| 2018 Q4 | 2.64 Billion USD | 4.99% |
| 2018 FY | 2.64 Billion USD | 14.9% |
| 2018 Q1 | 2.3 Billion USD | 0.15% |
| 2018 Q2 | 2.39 Billion USD | 3.95% |
| 2018 Q3 | 2.51 Billion USD | 5.12% |
| 2017 Q1 | 1.6 Billion USD | -1.91% |
| 2017 FY | 2.3 Billion USD | 40.52% |
| 2017 Q4 | 2.3 Billion USD | -3.02% |
| 2017 Q3 | 2.37 Billion USD | 44.82% |
| 2017 Q2 | 1.63 Billion USD | 2.0% |
| 2016 FY | 1.63 Billion USD | 62.65% |
| 2016 Q1 | 1.1 Billion USD | 9.58% |
| 2016 Q4 | 1.63 Billion USD | 6.11% |
| 2016 Q3 | 1.54 Billion USD | 8.9% |
| 2016 Q2 | 1.41 Billion USD | 28.45% |
| 2015 Q2 | 930.33 Million USD | 7.85% |
| 2015 FY | 1 Billion USD | 21.37% |
| 2015 Q4 | 1 Billion USD | 8.1% |
| 2015 Q1 | 862.62 Million USD | 3.92% |
| 2015 Q3 | 931.93 Million USD | 0.17% |
| 2014 Q2 | 679.1 Million USD | 1.84% |
| 2014 Q4 | 830.06 Million USD | 5.71% |
| 2014 Q1 | 666.82 Million USD | 5.92% |
| 2014 Q3 | 785.26 Million USD | 15.63% |
| 2014 FY | 830.06 Million USD | 31.85% |
| 2013 Q4 | 629.56 Million USD | 76.15% |
| 2013 FY | 629.56 Million USD | 90.54% |
| 2013 Q1 | 330.28 Million USD | -0.04% |
| 2013 Q2 | 334.21 Million USD | 1.19% |
| 2013 Q3 | 357.4 Million USD | 6.94% |
| 2012 Q4 | 330.41 Million USD | 11.43% |
| 2012 FY | 330.41 Million USD | 0.44% |
| 2012 Q1 | 293.59 Million USD | -10.75% |
| 2012 Q2 | 311.97 Million USD | 6.26% |
| 2012 Q3 | 296.53 Million USD | -4.95% |
| 2011 Q2 | 416.66 Million USD | -9.34% |
| 2011 FY | 328.96 Million USD | -32.81% |
| 2011 Q4 | 328.96 Million USD | -11.38% |
| 2011 Q3 | 371.22 Million USD | -10.91% |
| 2011 Q1 | 459.6 Million USD | -6.12% |
| 2010 Q1 | 502.66 Million USD | -29.44% |
| 2010 FY | 489.58 Million USD | -31.28% |
| 2010 Q4 | 489.58 Million USD | 5.37% |
| 2010 Q3 | 464.64 Million USD | -5.88% |
| 2010 Q2 | 493.68 Million USD | -1.79% |
| 2009 FY | 712.39 Million USD | 206.55% |
| 2009 Q1 | 189.63 Million USD | -18.4% |
| 2009 Q3 | 472.81 Million USD | 197.34% |
| 2009 Q2 | 159.01 Million USD | -16.15% |
| 2009 Q4 | 712.39 Million USD | 50.67% |
| 2008 Q4 | 232.38 Million USD | -12.21% |
| 2008 Q1 | 237.01 Million USD | -14.03% |
| 2008 Q2 | 204.73 Million USD | -13.62% |
| 2008 Q3 | 264.71 Million USD | 29.3% |
| 2008 FY | 232.38 Million USD | -15.71% |
| 2007 FY | 275.69 Million USD | -22.03% |
| 2007 Q1 | 324.93 Million USD | -8.11% |
| 2007 Q3 | 282.68 Million USD | -8.46% |
| 2007 Q4 | 275.69 Million USD | -2.47% |
| 2007 Q2 | 308.79 Million USD | -4.97% |
| 2006 Q3 | 464.88 Million USD | 23.93% |
| 2006 Q1 | 398.75 Million USD | 6.59% |
| 2006 Q4 | 353.6 Million USD | -23.94% |
| 2006 FY | 353.6 Million USD | -5.48% |
| 2006 Q2 | 375.11 Million USD | -5.93% |
| 2005 FY | 374.1 Million USD | -27.63% |
| 2005 Q1 | 487.45 Million USD | -5.7% |
| 2005 Q2 | 436.64 Million USD | -10.42% |
| 2005 Q3 | 398.1 Million USD | -8.83% |
| 2005 Q4 | 374.1 Million USD | -6.03% |
| 2004 FY | 516.91 Million USD | 36.19% |
| 2004 Q1 | 582.46 Million USD | 53.46% |
| 2004 Q2 | 538.11 Million USD | -7.61% |
| 2004 Q4 | 516.91 Million USD | 9.86% |
| 2004 Q3 | 470.5 Million USD | -12.56% |
| 2003 Q1 | 496.87 Million USD | -10.01% |
| 2003 FY | 379.54 Million USD | -31.26% |
| 2003 Q4 | 379.54 Million USD | -8.64% |
| 2003 Q3 | 415.43 Million USD | -11.7% |
| 2003 Q2 | 470.47 Million USD | -5.31% |
| 2002 Q4 | 552.13 Million USD | -8.44% |
| 2002 FY | 552.13 Million USD | -21.74% |
| 2002 Q1 | 666.84 Million USD | -5.49% |
| 2002 Q2 | 645.73 Million USD | -3.17% |
| 2002 Q3 | 603.05 Million USD | -6.61% |
| 2001 Q4 | 705.55 Million USD | -14.54% |
| 2001 FY | 705.55 Million USD | -20.44% |
| 2001 Q1 | 851.94 Million USD | -3.93% |
| 2001 Q2 | 852.06 Million USD | 0.01% |
| 2001 Q3 | 825.64 Million USD | -3.1% |
| 2000 Q2 | 876.63 Million USD | 0.11% |
| 2000 Q1 | 875.69 Million USD | 294.63% |
| 2000 FY | 886.82 Million USD | 299.65% |
| 2000 Q3 | 865.92 Million USD | -1.22% |
| 2000 Q4 | 886.82 Million USD | 2.41% |
| 1999 FY | 221.9 Million USD | -3.65% |
| 1999 Q1 | 250.8 Million USD | 8.9% |
| 1999 Q2 | 224.2 Million USD | -10.61% |
| 1999 Q3 | 209.7 Million USD | -6.47% |
| 1999 Q4 | 221.9 Million USD | 5.82% |
| 1998 Q4 | 230.3 Million USD | -1.16% |
| 1998 Q3 | 233 Million USD | 6.3% |
| 1998 FY | 230.3 Million USD | 19.26% |
| 1998 Q2 | 219.2 Million USD | 0.05% |
| 1998 Q1 | 219.1 Million USD | 13.46% |
| 1997 FY | 193.1 Million USD | 188.64% |
| 1997 Q1 | 79.6 Million USD | 18.98% |
| 1997 Q2 | 76.6 Million USD | -3.77% |
| 1997 Q3 | 181.1 Million USD | 136.42% |
| 1997 Q4 | 193.1 Million USD | 6.63% |
| 1996 Q4 | 66.9 Million USD | -10.08% |
| 1996 Q3 | 74.4 Million USD | 12.73% |
| 1996 Q2 | 66 Million USD | 6.28% |
| 1996 Q1 | 62.1 Million USD | 7.44% |
| 1996 FY | 66.9 Million USD | 15.74% |
| 1995 FY | 57.8 Million USD | 101.39% |
| 1995 Q2 | 23 Million USD | -13.86% |
| 1995 Q3 | 20 Million USD | -13.04% |
| 1995 Q4 | 57.8 Million USD | 189.0% |
| 1995 Q1 | 26.7 Million USD | -6.97% |
| 1994 FY | 28.7 Million USD | 63.07% |
| 1994 Q1 | 15.3 Million USD | -13.07% |
| 1994 Q2 | 13.3 Million USD | -13.07% |
| 1994 Q3 | 19.1 Million USD | 43.61% |
| 1994 Q4 | 28.7 Million USD | 50.26% |
| 1993 Q3 | 3.4 Million USD | 0.0% |
| 1993 Q4 | 17.6 Million USD | 417.65% |
| 1993 FY | 17.6 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -715.462% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -623.72% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -771.871% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -3997.851% |
| bluebird bio, Inc. | 619.16 Million USD | -995.371% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -5289.297% |
| Imunon, Inc. | 21.91 Million USD | -30842.995% |
| Editas Medicine, Inc. | 499.15 Million USD | -1258.723% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 74.581% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -102.116% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -465.789% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -108.59% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -381.35% |
| Verastem, Inc. | 149.71 Million USD | -4429.921% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 91.631% |
| Waters Corporation | 4.62 Billion USD | -46.581% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 93.13% |
| Biogen Inc. | 26.84 Billion USD | 74.736% |
| Nektar Therapeutics | 398.03 Million USD | -1603.906% |
| Perrigo Company plc | 10.8 Billion USD | 37.256% |
| Dynavax Technologies Corporation | 997.09 Million USD | -580.186% |
| Illumina, Inc. | 10.11 Billion USD | 32.923% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -23888.443% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -769.11% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -2948.056% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -10224.413% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 0.87% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -4002.412% |
| Evolus, Inc. | 188.99 Million USD | -3488.454% |
| Adicet Bio, Inc. | 207.29 Million USD | -3171.718% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -3335.631% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 79.498% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -3195.549% |
| FibroGen, Inc. | 423.52 Million USD | -1501.332% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 36.987% |
| OPKO Health, Inc. | 2.01 Billion USD | -237.133% |
| Homology Medicines, Inc. | 47.05 Million USD | -14312.536% |
| Geron Corporation | 394.07 Million USD | -1621.015% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -77.084% |
| Exelixis, Inc. | 2.94 Billion USD | -130.499% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -1740.513% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -4292.955% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -421.309% |
| Zoetis Inc. | 14.28 Billion USD | 52.526% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1052.957% |
| Abeona Therapeutics Inc. | 64 Million USD | -10496.711% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 70.163% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -12021.945% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -126.821% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -107.748% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -991.218% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -291.29% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -546.377% |
| Insmed Incorporated | 1.32 Billion USD | -409.995% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1957.759% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -269.617% |